Abstract
Abciximab Monoclonal antibody fragment inhibitor of the platelet glycoprotein IIb/IIIa receptor complex. Over a series of randomized clinical trials (EPIC, EPILOG, CAPTURE), it demonstrated its effectiveness in reducing ischemic complications of percutaneous coronary intervention. It is the first agent of its class approved for use in the setting of high-risk coronary angioplasty by the U.S. Food and Drug Administration.
Keywords
- Percutaneous Coronary Intervention
- Acute Myocardial Infarction
- Thrombin Generation
- Thrombolytic Agent
- Tissue Factor Pathway Inhibitor
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Kluwer Academic Publishers
About this chapter
Cite this chapter
Hodgson, P.K., Harrington, R.A. (1997). A Glossary of Terms in Thrombocardiology. In: Becker, R.C. (eds) Textbook of Coronary Thrombosis and Thrombolysis. Developments in Cardiovascular Medicine, vol 193. Springer, Boston, MA. https://doi.org/10.1007/978-0-585-33754-8_46
Download citation
DOI: https://doi.org/10.1007/978-0-585-33754-8_46
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-7923-9923-0
Online ISBN: 978-0-585-33754-8
eBook Packages: Springer Book Archive